Abcuro, Inc.
↗Newton, Massachusetts, USA
Abcuro is a clinical-stage biotechnology company focused on developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer. The company's platform targets KLRG1 (killer cell lectin-like receptor G1), a checkpoint receptor expressed on highly differentiated effector T cells and NK cells that are often the drivers of chronic inflammation and tissue damage.
Their lead candidate, ABC008, is a monoclonal antibody designed to selectively deplete KLRG1-expressing cells while sparing regulatory and memory T cells. This precision approach aims to treat diseases like Inclusion Body Myositis (IBM) and T-cell Large Granular Lymphocytic Leukemia (T-LGLL) without the broad immunosuppression associated with traditional therapies.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunology & Oncology therapeutics
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M (Pre-revenue)
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$215M
Investors:Bain Capital Life Sciences, Redmile Group, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Venture Partners, Pontifax, BlackRock
PIPELINE
Stage:Phase 2/3
Lead Drug Stage:Phase 2/3 (ABC008 for IBM)
Modalities:Monoclonal antibody (mAb)
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Sanofi (Strategic investment and potential collaboration interest)
COMPETITION
Position:Emerging
Competitors:Argenx, Kezar Life Sciences, Kyverna Therapeutics, Priovant Therapeutics
LEADERSHIP
Key Executives:
Alexandre LeBeaut - CEO
Jeffrey Soderman - Chief Business Officer
H. Jeffrey Wilkins - Chief Medical Officer
Scientific Founders:Stefano Romeo, Philip J. Brooks
Board Members:Adam Koppel (Bain Capital), Tiba Aynechi (Samsara BioCapital), Josh Resnick (RA Capital)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Abcuro, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.